Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166772 | 1.00 | MEN1 (0.50) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL29395053 | 0.89 | LTA4H (0.62) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL9393008 | 0.86 | RAB9A (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL8362464 | 0.83 | LTA4H (0.56) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL20353588 | 0.83 | ROCK2 (0.60) | ROCK2ROCK1 | |
| SCHEMBL25266534 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL4609213 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL30427471 | 0.82 | MEN1 (0.55) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL7618233 | 0.82 | LTA4H (0.61) | MEN1KMT2AMAPTCYP1A2POLB | |
| SCHEMBL15465921 | 0.81 | MAPT (0.62) | MEN1KMT2AMAPTCYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335509-B1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | VALENTA INTELLEKT LTD (RU) | 2026-03-11 | — | — | EP | disclosed |
| EP-3632433-B1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | NEBOLSIN VLADIMIR EVGENIEVICH (RU) | 2025-12-24 | — | — | EP | disclosed |
| US-12077551-B2 | Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “Z THERAPEUTICS” (RU) | 2024-09-03 | — | — | US | disclosed |
| US-20240116898-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | LTD "VALENTA-INTELLEKT" (RU) | 2024-04-11 | — | — | US | disclosed |
| EP-4335509-A2 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | LTD "VALENTA-INTELLEKT" (RU) | 2024-03-13 | — | — | EP | disclosed |
| US-11845740-B2 | Glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | LTD “Valenta-Intellekt” (RU) | 2023-12-19 | — | — | US | disclosed |
| US-11439631-B2 | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | “ChemImmune Therapeutics” Limited Liability Company (RU) | 2022-09-13 | — | — | US | disclosed |
| US-20210246149-A1 | A NEW ZINC COMPLEX, PREPARATION THEREOF AND USE THEREOF FOR TRERAPY OF HUMAN AND ANIMAL DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "Z THERAPEUTICS" (RU) | 2021-08-12 | — | — | US | disclosed |
| EP-3843724-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | National Health Research Institutes (TW) | 2021-07-07 | — | — | EP | disclosed |
| EP-3842445-A1 | NOVEL ZINC COMPLEX, PRODUCTION AND USE OF SAME | Obschestvo s Ogranichennoi Otvetstvennostiyu "Z Therapeutics" (RU) | 2021-06-30 | — | — | EP | disclosed |
| CN-112752764-A | Novel zinc complexes, their production and use | Z疗法有限责任公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20200188379-A1 | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO THE ABERRANT ACTIVITY OF CYTOKINES | "ChemImmune Therapeutics" Limited Liability Company (RU) | 2020-06-18 | — | — | US | disclosed |
| CN-111093661-A | Use of glutarimide derivatives for the treatment of diseases associated with abnormal activity of cytokines | 化学免疫疗法有限责任公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3632433-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" (RU) | 2020-04-08 | — | — | EP | disclosed |
| US-20200087285-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2020-03-19 | — | — | US | disclosed |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-10 | — | — | US | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020040670-A1 | NOVEL ZINC COMPLEX, PRODUCTION AND USE OF SAME | Общество с ограниченной ответственностью "ЗЕТ Терапевтикс" | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116898-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | GLS, GLS2, QPCT | MEN1 2797/4885KMT2A 3132/4885MAPT 4817/4885 |
| US-20210246149-A1 | A NEW ZINC COMPLEX, PREPARATION THEREOF AND USE THEREOF FOR TRERAPY OF HUMAN AND ANIMAL DISEASES | SLC7A11, GCLC, SLC39A7 | MEN1 2848/4885KMT2A 1747/4885MAPT 2669/4885 |
| US-11439631-B2 | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | CCL2, CCL11, CX3CR1 | MEN1 4391/4885KMT2A 4580/4885MAPT 2719/4885 |
| US-12077551-B2 | Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases | SLC7A11, SLC39A7, GCLC | MEN1 2586/4885KMT2A 1510/4885MAPT 2262/4885 |
| US-20200087285-A1 | NOVEL GLUTAMINYL CYCLASE INHIBITORS AND THE USE THEREOF IN TREATMENT OF VARIOUS DISEASES | GLS, GLS2, QPCT | MEN1 2879/4885KMT2A 3142/4885MAPT 4800/4885 |
| US-11845740-B2 | Glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases | GLS, GLS2, QPCT | MEN1 2582/4885KMT2A 3244/4885MAPT 4784/4885 |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | GLUL, GLS2, GLS | MEN1 2239/4885KMT2A 1698/4885MAPT 108/4885 |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | GLUL, GLS2, GLS | MEN1 2239/4885KMT2A 1698/4885MAPT 108/4885 |
| US-20200188379-A1 | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO THE ABERRANT ACTIVITY OF CYTOKINES | CCL2, CCL11, CX3CR1 | MEN1 4391/4885KMT2A 4580/4885MAPT 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.